DDX16 Inhibitors

Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16 Inhibitors encompasses a diverse range of compounds postulated to attenuate the functional activities of the DHX16 protein. As its name suggests, the primary function of DHX16 is to act as an ATP-dependent RNA helicase, playing a pivotal role in pre-mRNA splicing, a molecular process where introns (non-coding sequences) are removed from pre-mRNA molecules, and exons (coding sequences) are subsequently joined to form mature mRNAs. Within this realm, DHX16 is particularly integral in the minor spliceosome, responsible for the splicing of U12-type introns in pre-mRNAs. Additionally, beyond its splicing activity, DHX16 is implicated in the innate antiviral response, sensing splicing signals in viral RNA and acting as a pattern recognition receptor.

Inhibitors of DHX16, based on the table provided earlier, primarily target the fundamental mechanisms that underpin DHX16's functionality. For instance, compounds such as Adenosine and Suramin might act by targeting the ATP binding or hydrolysis sites on DHX16, thereby curtailing its ATP-dependent helicase activity. Given that DHX16 relies on ATP for its function, the inhibition of its ATPase activity would fundamentally disrupt its role in pre-mRNA splicing. Other compounds, such as Oxaliplatin and Camptothecin, introduce DNA damage or impede DNA synthesis, respectively. Such disruptions could induce cellular responses that downregulate DHX16 as part of an overarching mechanism to mitigate damage or maintain cellular homeostasis. In contrast, compounds like Emetine and Actinomycin D may operate more indirectly, either by curbing overall protein synthesis or by binding DNA to inhibit RNA synthesis. Although these actions don't target DHX16 directly, they might indirectly affect the availability of substrates or the cellular environment, leading to a diminished expression or activity of DHX16.